CY1111941T1 - Χρηση ενος μοριου νουκλεϊνικου οξεως το οποιο κωδικοποιει τον τομεα δισιντεγρινης μιας αδαμαλυσινης ως αντι-αγγειογονου, αντι-διεισδυτικου και αντι-μεταστατικου παραγοντα - Google Patents
Χρηση ενος μοριου νουκλεϊνικου οξεως το οποιο κωδικοποιει τον τομεα δισιντεγρινης μιας αδαμαλυσινης ως αντι-αγγειογονου, αντι-διεισδυτικου και αντι-μεταστατικου παραγονταInfo
- Publication number
- CY1111941T1 CY1111941T1 CY20111100367T CY111100367T CY1111941T1 CY 1111941 T1 CY1111941 T1 CY 1111941T1 CY 20111100367 T CY20111100367 T CY 20111100367T CY 111100367 T CY111100367 T CY 111100367T CY 1111941 T1 CY1111941 T1 CY 1111941T1
- Authority
- CY
- Cyprus
- Prior art keywords
- tumor
- operably linked
- sequence
- mammal
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A61N1/303—Constructional details
- A61N1/306—Arrangements where at least part of the apparatus is introduced into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Radiology & Medical Imaging (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Η παρούσα εφεύρεση αφορά τη χρήση, στην παρασκευή ενός φαρμάκου για την αναστολή της αγγειογενέσεως ή της διεισδύσεως και/ή του σχηματισμού μεταστάσεων, ενός δραστικού παράγοντα επιλεγόμενου από μία πρωτεϊνική ουσία περιλαμβάνουσα ή αποτελούμενη από το σύνολο ή ένα τμήμα του τομέα δισιντεγρίνης μίας αδαμαλυσίνης ή ενός παραγώγου της, ένα μόριο νουκλεϊνικού οξέως περιλαμβάνον ή αποτελούμενο από μία πολυνουκλεοτιδική αλληλουχία η οποία κωδικοποιεί το σύνολο ή τμήμα του τομέα δισιντεγρίνης μίας αδαμαλυσίνης ή ενός παραγώγου της. Πλεονεκτικά, η αδαμαλυσίνη είναι η μεταργιδίνη.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0110015A FR2827775B1 (fr) | 2001-07-26 | 2001-07-26 | Utilisation dans une composition anti-angiogenique du domaine disintegrine d'adamalysine |
| EP02774845A EP1409008B1 (fr) | 2001-07-26 | 2002-07-26 | Utilisation d'une molécule d'acide nucléique codant le domaine disintegrine d'une adamalysine comme agent anti-angiogenique, anti-invasif et anti-metastatique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111941T1 true CY1111941T1 (el) | 2015-11-04 |
Family
ID=8865951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100367T CY1111941T1 (el) | 2001-07-26 | 2011-04-08 | Χρηση ενος μοριου νουκλεϊνικου οξεως το οποιο κωδικοποιει τον τομεα δισιντεγρινης μιας αδαμαλυσινης ως αντι-αγγειογονου, αντι-διεισδυτικου και αντι-μεταστατικου παραγοντα |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8207137B2 (el) |
| EP (1) | EP1409008B1 (el) |
| JP (1) | JP4332423B2 (el) |
| CN (1) | CN1321689C (el) |
| AT (1) | ATE495754T1 (el) |
| CA (1) | CA2453561C (el) |
| CY (1) | CY1111941T1 (el) |
| DE (1) | DE60238986D1 (el) |
| DK (1) | DK1409008T3 (el) |
| ES (1) | ES2359394T3 (el) |
| FR (1) | FR2827775B1 (el) |
| IL (2) | IL159986A0 (el) |
| PT (1) | PT1409008E (el) |
| WO (1) | WO2003009866A1 (el) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1759714A1 (en) * | 2005-09-02 | 2007-03-07 | Bioalliance Pharma | Electrotransfer of nucleic acid into tissue cells |
| US9101581B2 (en) | 2008-10-27 | 2015-08-11 | Eyegene Inc. | Method for treating vascular-related disease |
| CN101379082A (zh) | 2006-01-19 | 2009-03-04 | 爱吉恩公司 | 治疗血管相关疾病的包含肽的药物组合物 |
| EP1984391A4 (en) * | 2006-01-19 | 2009-08-12 | Eyegene Inc | PEPTIDE-SUBSTANCED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES CONNECTED WITH THE VASCULAR SYSTEM |
| EP1970441A1 (en) * | 2007-03-06 | 2008-09-17 | BioAlliance Pharma | Plasmid containing a sequence encoding a disintegrin domain of metargidin (RDD) |
| EP2353607A1 (en) | 2010-02-04 | 2011-08-10 | BioAlliance Pharma | Use of disintegrin domain of an adamalysin for the treatment of psoriasis |
| JP2013519374A (ja) * | 2010-02-11 | 2013-05-30 | ユニバーシティー オブ サザン カリフォルニア | 修飾されたａｄａｍディスインテグリンドメインポリペプチドおよびその使用 |
| KR101338473B1 (ko) | 2011-09-20 | 2013-12-10 | 연세대학교 산학협력단 | 미세소낭성 ａｄａｍ１５를 유효성분으로 포함하는 암 예방 또는 치료용 약제학적 조성물 |
| WO2021185719A1 (en) * | 2020-03-15 | 2021-09-23 | Ac Bioscience Sa | Rgd-containing peptide and use thereof for cancer treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5814609A (en) * | 1993-10-22 | 1998-09-29 | University Of Southern California | Compositions containing a disintegrin and methods for its use in preventing metastasis and other conditions |
| AU3212400A (en) * | 1999-01-22 | 2000-08-07 | Human Genome Sciences, Inc. | Metalloproteinase adam 22 |
| AU5043200A (en) * | 1999-05-27 | 2000-12-18 | Human Genome Sciences, Inc. | Adam polynucleotides and polypeptides |
| EP1803810A1 (en) * | 2000-02-25 | 2007-07-04 | Immunex Corporation | Integrin antagonists |
| AU4721901A (en) * | 2000-02-25 | 2001-09-03 | Immunex Corp | Integrin antagonists |
| CA2399913A1 (en) * | 2000-03-03 | 2001-09-13 | Human Genome Sciences, Inc. | Adam polynucleotides, polypeptides, and antibodies |
| US6294368B1 (en) * | 2001-03-22 | 2001-09-25 | Applera Corporation | Isolated human metalloprotease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
-
2001
- 2001-07-26 FR FR0110015A patent/FR2827775B1/fr not_active Expired - Fee Related
-
2002
- 2002-07-26 ES ES02774845T patent/ES2359394T3/es not_active Expired - Lifetime
- 2002-07-26 EP EP02774845A patent/EP1409008B1/fr not_active Expired - Lifetime
- 2002-07-26 DK DK02774845.8T patent/DK1409008T3/da active
- 2002-07-26 AT AT02774845T patent/ATE495754T1/de active
- 2002-07-26 PT PT02774845T patent/PT1409008E/pt unknown
- 2002-07-26 DE DE60238986T patent/DE60238986D1/de not_active Expired - Lifetime
- 2002-07-26 WO PCT/FR2002/002691 patent/WO2003009866A1/fr active Application Filing
- 2002-07-26 IL IL15998602A patent/IL159986A0/xx active IP Right Grant
- 2002-07-26 CN CNB02814760XA patent/CN1321689C/zh not_active Expired - Fee Related
- 2002-07-26 CA CA2453561A patent/CA2453561C/fr not_active Expired - Fee Related
- 2002-07-26 JP JP2003515258A patent/JP4332423B2/ja not_active Expired - Fee Related
-
2004
- 2004-01-21 IL IL159986A patent/IL159986A/en not_active IP Right Cessation
- 2004-01-26 US US10/764,628 patent/US8207137B2/en not_active Expired - Fee Related
-
2011
- 2011-04-08 CY CY20111100367T patent/CY1111941T1/el unknown
-
2012
- 2012-05-22 US US13/477,181 patent/US20130158502A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003009866A1 (fr) | 2003-02-06 |
| PT1409008E (pt) | 2011-04-18 |
| US20130158502A1 (en) | 2013-06-20 |
| ES2359394T3 (es) | 2011-05-23 |
| CA2453561A1 (fr) | 2003-02-06 |
| IL159986A (en) | 2011-01-31 |
| US20040171549A1 (en) | 2004-09-02 |
| JP4332423B2 (ja) | 2009-09-16 |
| EP1409008B1 (fr) | 2011-01-19 |
| CA2453561C (fr) | 2013-03-12 |
| JP2005502638A (ja) | 2005-01-27 |
| CN1535156A (zh) | 2004-10-06 |
| CN1321689C (zh) | 2007-06-20 |
| EP1409008A1 (fr) | 2004-04-21 |
| FR2827775A1 (fr) | 2003-01-31 |
| ATE495754T1 (de) | 2011-02-15 |
| US8207137B2 (en) | 2012-06-26 |
| DK1409008T3 (da) | 2011-05-16 |
| IL159986A0 (en) | 2004-06-20 |
| FR2827775B1 (fr) | 2003-09-26 |
| DE60238986D1 (de) | 2011-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111941T1 (el) | Χρηση ενος μοριου νουκλεϊνικου οξεως το οποιο κωδικοποιει τον τομεα δισιντεγρινης μιας αδαμαλυσινης ως αντι-αγγειογονου, αντι-διεισδυτικου και αντι-μεταστατικου παραγοντα | |
| ATE320815T1 (de) | Verwendung einer neurotoxintherapie zur behandlung von prostata erkrankungen | |
| ATE423134T1 (de) | Verbesserte sezernierung von neublastin | |
| KR970000808B1 (en) | Human proapolipoprotein a-1 expression | |
| ATE255635T1 (de) | Polypeptid, fähig zur inhibierung der bindung zwischen menschliches il-6 und dessen rezeptor | |
| MX9602993A (es) | Hormona del crecimiento humano. | |
| JP2006512097A5 (el) | ||
| WO2004110371A3 (en) | Method for the treatment of malignancies | |
| WO2002083080A3 (en) | Method of treating arthritis using lentiviral vectors in gene therapy | |
| EP2114431A4 (en) | ARAZYME-CONTAINING COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER | |
| WO1997022695A3 (fr) | Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer | |
| WO2002059346A3 (en) | Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents | |
| DE69736276D1 (de) | Menschliche dnase resistent gegen actininhibitoren | |
| KR970701724A (ko) | 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin) | |
| WO1987007472A3 (en) | A dna sequence encoding the mas oncogene, polypeptides encoded therefrom, and diagnostic and other methods based thereon | |
| PT914417E (pt) | Dnase ii humana | |
| WO2000026362A3 (de) | Proteine der stomatinfamilie und ihre verwendung als zielproteine für die schmerztherapie | |
| WO2023183550A3 (en) | Messenger ribonucleic acids with extended half-life | |
| ATE448311T1 (de) | Hybridprotein und dafür kodierender vektor zur inhibition der angiogenese | |
| EP1279332A3 (en) | Transgenic non-human mammal |